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viewed as separate pathophysiological entities, in part because
of their differential anatomical localization as well as their
distinct clinical manifestations.1,2 This view has been recently
challenged by the demonstration of a link between deep vein
thrombosis (DVT)andthepresenceof subclinical atherosclerosis
and higher risk of subsequent cardiovascular (CV) events,3,4
raising thehypothesis that arterial andvenous thrombosis share
common mechanisms that contribute to endothelial dysfunc-
tion, a key pathogenic step in atherogenesis.5,6
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Abstract Mechanisms linking deep vein thrombosis (DVT) and subclinical atherosclerosis and
risk of cardiovascular events are poorly understood. The aim of this study was to
investigate the potential impact of CX3CR1/CX3CL1 axis in DVT-associated endothelial
dysfunction. The study included 22 patients (age: 37.5  8.2 years) with a history of
idiopathic DVT and without known cardiovascular risk factors and 23 aged-matched
control subjects (age: 34  7.8 years). Flow cytometry was used to evaluate peripheral
markers of platelet activation, leukocyte immunophenotypes and CX3CR1/CX3CL1
expression in both groups. A flow chamber assay was employed to measure leukocyte
arrest under dynamic conditions. Platelet activation and the percentage of circulating
CX3CR1-expressing platelets, CX3CR1-expressing platelet-bound monocytes and CD8
þ
lymphocytes were higher in patients with DVT than in controls. Additionally, patients
with DVT had increased plasma levels of CX3CL1, soluble P-selectin and platelet factor
4/CXCL4. Interestingly, this correlated with enhanced platelet–leukocyte interaction
and leukocyte adhesion to TNFα-stimulated arterial endothelial cells, which was partly
dependent on endothelial CX3CL1 upregulation and increased CX3CR1 expression on
platelets, monocytes and lymphocytes. In conclusion, increased CX3CR1 expression on
circulating platelets may constitute a prognostic marker for long-term adverse
cardiovascular events in patients with DVT. Blockade of CX3CL1/CX3CR1 axis may
represent a new therapeutic strategy for the prevention of cardiovascular comorbid-
ities associated with DVT.
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Endothelial dysfunction occurs early in the process of
atherogenesis and triggers a proinflammatory and prothrom-
botic phenotype in the endothelium,7 provoking the binding
and subsequent migration of leukocytes. Indeed, adhesive
interactions between leukocytes and endothelium precede
leukocyte infiltration into the subendothelial space during
early athersclerosis.7–9 The migration of leukocytes from
circulation to sites of extravascular injury ismediated through
a sequential cascade of leukocyte–endothelial cell adhesive
interactions that involve an array of cell adhesion molecules
(CAMs) present on leukocytes and endothelial cells.10 In addi-
tion to CAMs, chemoattractant molecules such as chemokines
have thepotential to recruit specific cell types and are involved
in regulation of leukocyte trafficking.11Among them, fractalk-
ine (CX3CL1) is a unique member of the CX3C subfamily that
exists both as a soluble form, inducing chemotaxis, and as a
membrane-bound form on the surface of inflamed endothe-
lium, promoting cell–cell adhesion; in both cases, this involves
activation of its cognate receptor CX3CR1.12 Interestingly,
circulating CX3CL1 has been recently associated with both
atherosclerosis13,14 and diabetes;15 however, its potential
involvement in DVT is unknown.
Platelets are known to play critical roles in DVT and
atherosclerosis.16,17 Platelet tethering and activation results
in the secretion of inflammatory cytokines and in the
expression of platelet surface P-selectin and other CAMs,
which collectively contribute to the inflammatory state of
endothelial cells in the vascular wall.18,19 These local cellular
changes lead to the activation of coagulation pathways and
the development of DVT.20 However, studies investigating
whether platelet activation is present in the stable phase of
DVT in young patients are limited.
In the present study, we tested the hypothesis that platelet
activation, circulating levels of fractalkine/CX3CL1 and inflam-
matory markers of endothelial damage are elevated long term
in younger patients with a single episode of idiopathic DVT.
The objective of the study was therefore to explore the func-
tional role of CX3CL1/CX3CR1 axis in those patients.
Methods
Study Population
The study conformed to the principles outlined in theDeclara-
tion of Helsinki for the use of human subjects. The study
protocol was approved by the Ethics Committee of the Uni-
versity Clinic Hospital of Valencia. Written informed consent
was obtained from all participants. Reporting of the study
conformed to the STROBE statement along with references to
STROBE and the broader EQUATOR guidelines.21
Consecutive patients (18–50 years of age) admitted to the
Internal Medicine Unit at the University Clinic Hospital of
Valencia (Spain) between January 2010and January 2015with
a symptomatic first episode of idiopathic DVT of the lower
limbs were potentially eligible for the study. The diagnosis of
DVTwas confirmed by echo Doppler examination. All patients
were treated in the acute phase with low-molecular-weight
heparin at a therapeutic dose and after with the vitamin K
antagonist dicumarol for 6months. Exclusion criteria for cases
and controls were the following: (1) transitory risk factors for
DVT, for example, <3 months after trauma or surgery, immo-
bilization, hormonal treatment or pregnancy; (2) congenital
thrombophilia, or other hypercoagulability states such as
antiphospholipid antibody syndrome, hyperhomocysteinae-
mia, chronic inflammatory diseases or cancer; (3) previous CV
events (acute myocardial infarction, coronary heart disease,
ischaemic or haemorrhagic stroke, and peripheral artery dis-
ease) or CV risk factors such as smoking, arterial hypertension
(systolic blood pressure >140 mm Hg and/or diastolic blood
pressure>90 mmHg), diabetesmellitus (plasma glucose level
of >126 mg/dL after an overnight fast, or use of antidiabetic
drugs), obesity (bodymass index>30), hypercholesterolaemia
(plasmacholesterol level>200mg/dL after anovernight fastor
use of lipid-lowering drugs); (4) renal disease or advanced
renal dysfunction (creatinine clearance <60 mL/min); (5)
hepatic insufficiency (Child-Pugh class B or C) or (6) psychia-
tric disorders that impairs adherence to treatment. The final
study group comprised 22 patients and the experimental
procedures was performed 1 year after the acute DVT event.
A control group of 23 healthy volunteers, age- and sex-
matched with the study group, were recruited. The demo-
graphic, clinical and laboratory characteristics of patients and
controls are shown in ►Table 1.
Laboratory Analyses
Blood was drawn by venipuncture after a fasting period of at
least 12 hours. For analyses, whole blood samples were either
heparinized or drawn in EDTA or sodium citrate. Serum was
centrifuged at 4,000  g for 10 minutes and frozen at 80°C
until analysis. Lipid serum levels (total, HDL and LDL choles-
terol, triglycerides), blood glucose, HbA1c, fibrinogen and
cellular countsweremeasured immediately. Soluble P-selectin
(sP-selectin)CX3CL1,platelet factor4 (PF4)/CXCL4andvascular
cell adhesionmolecule-1 (VCAM-1) were quantified in plasma
by ELISA using DuoSet kits from R&D Systems (Wiesbaden,
Germany).
Cell Culture
Human umbilical arterial endothelial cells (HUAECs) and
human umbilical vein endothelial cells (HUVECs) were iso-
lated by collagenase treatment as described22,23 and main-
tained in human endothelial cell–specific medium (EBM-2)
supplemented with endothelial growth medium (EGM-2)
and 10% foetal bovine serum (FBS). Cells up to passage 1were
grown to confluence to preserve endothelial features. Cells
were incubated for 16 hours in medium containing 1% FBS
prior to every experiment.
Flow Cytometry
To assess endothelial expression of CX3CL1, HUAEC and
HUVEC were grown to confluence and stimulated with
TNFα (20 ng/mL) for 24 hours. Cells were then detached
from culture flasks by scraping in ice-cold phosphate buf-
fered saline (PBS) containing 2 mM EDTA and recovered by
centrifugation. Washed cells (2  106 cells/mL) were incu-
bated with a phycoerythrin (PE)-conjugated monoclonal
antibody (Ab) against human CX3CL1 (R&D Systems) diluted
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1:25 in PBSwith 3%BSA, for 1 hour at 4°C in the dark. Samples
were run in a FACSVerse flowcytometer (BD Biosciences, San
Jose, California, United States) and the expression of CX3CL1
(PE fluorescence) was calculated as themean of fluorescence
intensity (MFI).
Platelet activation was measured by P-selectin (CD62P)
surface expression. Duplicate samples (6.25 μL) of citrated
blood, diluted 1:10 in glucose buffer (1 mg/mL glucose in
PBS/0.35% BSA), were incubated for 30 minutes in the dark
with a 5-carboxyfluorescein-conjugated Ab against human
CD41 (1.25 μL; Immunostep, Salamanca, Spain) and an
allophycocyanin-conjugated Ab against human P-selectin
(1.25 μL, Immunostep). The CD41þ population (platelets)
was selected according to the gating strategy illustrated
in ►Supplementary Fig. S1 [available online only], and
expressed as the percentage of positive platelets.
To determine CX3CR1 expression on platelets, circulating
monocytes and lymphocytes, duplicate samples (20 μL) of
heparinized whole blood were incubated in the dark for
30 minutes with saturated amounts of a PE-conjugated Ab
against human CX3CR1 (R&D Systems) or an PE-conjugated
isotype control Ab (BD Biosciences). In some experiments,
blood samples were incubatedwith 10 mM EDTA (15minutes
at 37°C) to promote platelet dissociation, as described.24 Red
blood cells were lysed and leukocytes were fixed using a
commercial lysis buffer (BD Pharm Lyse, BD Biosciences).
Expression of CX3CR1 (PE fluorescence) was measured on
CD41þ (platelets),CD14þ (monocytes)andCD3þ (lymphocytes)
Table 1 Demographic and laboratory characteristics in young patients with a previous episode of idiopathic venous thrombosis
(DVT) and controls
Control group (n ¼ 23) DTV subjects (n ¼ 22) p-Value
Age (y) 34  7.8 37.5  8.2 1.41
Gender M/F (%) 7/16 (30.4/69.5%) 6/16 (27.3/72.7%) 0.13
BMI (kg/cm2) 23.7  3.5 25.41  3.9 0.09
Systolic BP (mm Hg) 106.6  10.3 111.5  10.7 0.12
Diastolic BP (mm Hg) 73.1  7.0 70.18  8.3 0.13
Glucose, mg/dL 90.8  11.2 93  10.1 0.55
Urea, mg/dL 34  8.4 30.5  7.1 0.19
Creatinine, mg/dL 0.73  0.1 0.7  0.2 0.58
Uric acid, mg/dL 4.83  1.5 5.01  1.5 0.71
Cholesterol, mg/dL 187.4  28.8 202  28.5 0.13
Triglycerides, mg/dL 76.2  44.8 114.1  113.3 0.23
Ferritin, ng/mL 63.6  60.0 63.5  68.4 0.99
Microalbuminuria, mg/L 9.11  9.6 27.7  72.7 0.38
Leukocytes count, per mL 6,460  1,371.5 8,185.9  9,815 0.50
Neutrophils (%) 56.5  9.03 59.2  11.5 0.43
Lymphocytes (%) 32.6  7.8 29.06  9.9 0.24
Monocytes (%) 5.8  1.9 5.33  1.9 0.45
Haemoglobin, g/dL 13.6  0.8 13.64  1.4 0.92
Platelet count,  109/L 257  49.8 221  36.4 0.15
ESR, mm 9.13  7.6 11.85  10.6 0.40
PT, s 10.5  0.7 10.7  0.8 0.47
QI, % 99.2  3.0 99.23  2.4 0.96
Fibrinogen, g/L 3.4  0.3 3.58  0.4 0.40
D Dimer, ng/mL 172.7  75.3 189.73  164.7 0.71
HbA1c, % 5.30  0.3 5.2  0.2 0.83
Homocysteine, µmol/L 10.6  5.8 9.9  2.0 0.59
ANA, ratio/quotient 0.78  1.0 0.9  2.0 0.78
TSH, µU/mL 2.51  1.5 2.2  1.2 0.56
Abbreviations: ANA, antinuclear antibodies; BMI, bodymass index; BP, blood pressuremean; ESR, erythrocyte sedimentation rate; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; PT, prothrombin time; QI, quick index; TSH, thyroid-stimulating hormone.
Notes: Data are expressed as mean  SEM. p < 0.05 relative to values in the control group.
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populations according to the gating strategy illustrated
in ►Supplementary Figs. S2 and S3 [available online only].
All samples were run in a FACSVerse flow cytometer (BD
Biosciences) and cell surface expression was calculated as the
meanofMFI.AllflowcytometrydatawereanalysedwithFlowJo
v10.0.7 software (FlowJo, Ashland, Oregon, United States).
Leukocyte–Endothelial Cell Interactions under Flow
Conditions
A dynamic flow chamber assay was used to examine leuko-
cyte–endothelial cell interactions in vitro using whole blood
diluted 1:10 in Hank’s buffered salt solution, as described.25,26
Cells were grown to confluence and stimulatedwith TNFα (20
ng/mL) for 24 hours. The flow chamber (GlycoTech, Rockville,
Maryland, United States) was assembled and placed onto an
inverted microscope stage. Diluted blood was then perfused
across the endothelial cell monolayers and cell interactions
weredeterminedafter 5-minute perfusion at 0.5dyn/cm. Cells
interacting on the surface of the endotheliumwere visualized
and recorded in phase contrast (20 objective, 10 eyepiece)
using a Zeis Axio Observer A1 microscope (Zeis, Thornwood,
New York, United States).
In parallel, some plateswere incubatedwith amonoclonal
neutralizing antibody against human CX3CL1 (5 μg/mL) or
with an isotype-matched control antibody (MOPC-21, 5 μg/
mL) added 10 minutes before blood perfusion. To evaluate
the contribution of platelets to leukocyte adhesion, the
experiments were performed in heparinized blood incu-
bated or not with 10 mM EDTA (15 minutes at 37°C).
Immunofluorescence Microscopy
To visualize adherent platelet–mononuclear cell complexes to
endothelial cells, we performed immunofluorescence analysis
after flow chamber assays. Cells were fixed with 4% parafor-
maldehyde and blocked in PBS containing 1% BSA. Then, cells
were incubated at 4°C overnight with a FITC-conjugated anti-
body against human CD45 (1:50 dilution) and an APC-con-
jugated antibody against human CD41 (1:50 dilution).
In additional experiments, confluent endothelial cells
were grown on glass coverslips and stimulated with TNFα
(20 ng/mL) for 24 hours. Cells were then fixed with 4%
paraformaldehyde and blocked in PBS containing 1% BSA.
Subsequently, cells were incubated at 4°C overnight with a
primary goat monoclonal Ab against human CX3CL1 (1:200
dilution) in 0.1% BSA/PBS, followed by incubation with a
fluorescein isothiocyanate-conjugated secondary rabbit
anti-goat Ab (1:1,000 dilution) at room temperature for
45 minutes. Cell nuclei were counterstained with 4’-6-dia-
midino-2-phenylindole. Images were captured with Zeis
Axio Observer A1 fluorescence microscope.
Statistical Analysis
Normality of data was analysed using the Shapiro–Wilk test.
Normally distributed values are expressed as percentage or
mean  SEM,whenappropriate. Non-parametric variables are
expressed as median and interquartile range (25th–75th). For
comparisons of two groups, Student’s t-test was used in data
that passed both normality and variance tests; otherwise, the
non-parametric Mann–Whitney U-test was performed. For
comparisons between multiple groups, one-way analysis of
variance followed by post hoc analysis (Bonferroni’s test) was
used in data that passed both normality and variance tests;
otherwise, the nonparametric Kruskal–Wallis test followed by
Dunn’s post hoc analysis was used. Data were considered
statistically significant at a p-value less than 0.05.
Results
Twenty-two patients with idiopathic DVT of the lower limbs
(6 males and 16 females, aged 37.5  8.2 years) and 23
healthy control subjects (7 males and 16 females, aged
34  7.8 years)were enrolled in the study. The demographic,
clinical and laboratory characteristics of patients and con-
trols are shown in ►Table 1. There were no statistically
significant differences between the two groups with regards
to age, sex and laboratory parameters (►Table 1).
Platelet Activation and CX3CR1 Expression Is Increased
in Patients with DVT
We compared platelet activation between the two groups by
flow cytometry. We found that platelet P-selectin expression
and the percentage of platelets expressing P-selectin was
significantly higher in young DVT patients than in controls
(►Fig. 1A, B, p < 0.05). Upon cell activation, P-selectin trans-
locates to the cell surfacewhere it can be cleaved and released
into blood as sP-selectin. We thus determined circulating
Fig. 1 P-selectin expression in platelets fromDVTpatients andage-matched
controlsbyflowcytometry. Plateletswere stainedwithconjugatedantibodies
against CD41 and P-selectin. Results are expressed as (A) mean fluorescence
intensity and (B) percentage of positive cells (n ¼ 23 age-matched controls,
n ¼ 22 DVT patients).p < 0.05 relative to values in the control group.
(C) Soluble P-selectin and (D) PF4/CXCL4 plasma levels were determined by
ELISA. Values are expressed as mean  SEM. p < 0.05 relative to values in
the control group. (n ¼ 23 age-matched controls, n ¼ 22 DVT patients).
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levels of sP-selectin in plasma by ELISA, finding that the levels
were significantly higher in the DVT group than in the control
group (►Fig. 1C, p < 0.05). Similarly, circulating plasma levels
of PF4/CXCL4, a platelet chemokine released upon platelet
activation, were significantly higher in young DVT patients
than in controls (►Fig. 1D, p < 0.05). Flow cytometry enabled
us to identify platelets using the gating strategy depicted
in ►Supplementary Fig S1 [available online only], and we
additionally found that the percentage of circulating platelets
expressing CX3CR1 receptor was significantly higher in DVT
patients than in controls (►Fig. 2A, B, p < 0.05), which was
accompanied by significantly higher plasma-soluble levels of
CX3CL1 (►Fig. 2C, p < 0.05). By contrast, no differences were
detected in the plasma levels of VCAM-1 between the two
groups (►Fig. 2D, p > 0.05).
CX3CR1 Expression on Monocytes and Lymphocytes Is
Increased in Patients with DVT
Monocyteswere identifiedbyflowcytometry using the gating
strategy shown in ►Supplementary Fig S2 [available online
only]. The percentage of CX3CR1-expressing monocytes was
significantly higher in heparinized whole blood from young
DVT patients than from age-matched controls (►Fig. 3A, B;
p < 0.05); however, CX3CR1 expression was lost when plate-
lets were dissociated from this leukocyte subset (►Fig. 3C, D).
Lymphocytes were also identified using the gating strategy
depicted in ►Supplementary Fig. S3 [available online only],
and we observed that CX3CR1 expression was also greater in
lymphocytes from DVT patients than from control subjects
(►Fig. 4A, B; p < 0.05), and was comparable to that found in
monocytes when platelets were dissociated (►Fig. 4C, D).
Circulating Leukocytes of DVT Patients Show
Increased Adhesiveness to TNFα-Stimulated HUAEC
To explore the functional consequences of these observations,
we examined the involvement of platelet CX3CR1 and CX3CL1-
dependent leukocyte–endothelial cell interactions under
dynamicflowconditions. First,weevaluatedCX3CL1expression
in arterial (HUAEC) andvenous (HUVEC) endothelial cells. To do
this, HUAEC andHUVECwere stimulatedwith TNFα (20 ng/mL)
for 24 hours to mimic dysfunctional endothelium. Flow cyto-
metry analysis revealed a clear upregulation of CX3CL1 expres-
sion in TNF-stimulated HUAEC and HUVEC as compared with
vehicle-treated cells (►Fig. 5A). These observations were con-
firmed by immunofluorescence studies (►Fig. 5B).
We then perfused heparinized blood from DVT patients
and controls across HUAEC and HUVEC monolayers that
were stimulated or not with TNFα, and evaluated leuko-
cyte–endothelial cell interactions. When whole blood from
DVT patients and their respective controls was perfused
Fig. 2 CX3CL1 receptor expression (CX3CR1) in platelets from DVT
patients and age-matched controls by flow cytometry. Heparinized
whole blood was co-stained with specific markers for CD41 and
CX3CR1. Results are expressed as (A) mean fluorescence intensity and
(B) percentage of positive cells (n ¼ 23 age-matched controls, n ¼ 22
DVT patients). (C) CX3CL1 and (D) VCAM-1 plasma levels were
measured by ELISA (n ¼ 23 age-matched controls, n ¼ 22 DVT
patients). p < 0.05 relative to values in the control group.
Fig. 3 CX3CL1 receptor expression (CX3CR1) in circulating mono-
cytes from DVT patients and age-matched controls. Heparinized
whole blood was co-stained with specific markers for monocytes and
CX3CR1. Blood samples were incubated or not with EDTA. Results are
expressed as (A, C) mean fluorescence intensity (MFI) and (B, D)
percentage of positive cells (n ¼ 23 age–matched controls, n ¼ 22
DVT patients). p < 0.05 relative to values in the control group.
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across TNFα-stimulated HUAEC, we found a significant
increase in leukocyte adhesion in both groups, which was
more marked using blood from the DVT group (►Fig. 6A,
p < 0.05). By contrast, no difference between the two groups
was found when the experiment was repeated using HUVEC
(►Fig. 6B). Neutralization of CX3CL1 activity on endothelial
cell surface resulted in a significant reduction of TNFα-
induced leukocyte adhesion to HUAEC (45%), but not to
HUVEC in the DVT group (►Fig. 6A, B). Of note, when
platelets were disaggregated from leukocytes with EDTA,
leukocyte adhesion to both HUAEC and HUVEC significantly
diminished in the DVT group (►Fig. 6C, D). In this case,
neutralization of CX3CL1 activity failed to affect leukocyte
adhesion to the dysfunctional endothelium (►Fig. 6C, D). To
corroborate these findings, we investigated adherent plate-
let–mononuclear cell complexes with endothelial cells by
immunofluorescence using platelet marker staining. Con-
firming our previous observations, when platelets were
disaggregated from leukocytes with EDTA, leukocyte adhe-
sion to HUAEC was notably diminished (►Supplementary
Fig. S4 [available online only]).
Discussion
Several studies have reported an association between ather-
osclerosis and venous thromboembolism. Patients with idio-
pathic venous thromboembolism have a higher risk of
developing symptomatic atherosclerosis than do patients
with the secondary form of the disease3,24 or the general
population.4 There is increasing evidence that inflammatory
processes and DVT are intimately linked, and recent data
have provided new insights into the inflammatory mechan-
isms involved in the acute stage of DVT.27 However, less is
known about the inflammatory status in the chronic phase
after the primary event of DVT in young patients and in the
absence of CV risk factors. Here,we provide thefirst evidence
that young patients with a previous idiopathic DVT have a
low-grade systemic inflammation even in the absence of CV
risk factors. Accordingly, patients had greater numbers of
activated circulating platelets with increased surface expres-
sion of P-selectin than controls, and thiswas accompanied by
a marked increase in plasma levels of sP-selectin, PF4/CXCL4
and CX3CL1. This activated status correlated with increased
platelet–leukocyte and leukocyte adhesion to TNFα-stimu-
lated human arterial endothelium, which was partly depen-
dent on arterial CX3CL1 upregulation and increased CX3CR1
expression on platelet–leukocyte aggregates in blood from
patients with DVT.
Plateletsare implicatedaskeymediators in thepathogenesis
of DVT.28–30 Correspondingly, activated platelets can mediate
the endothelial adhesion of circulating leukocytes, a feature
typical of dysfunctional endothelium that precedes atherogen-
esis.7 Upon activation, platelets express specific CAMs such as
P-selectin, and release several inflammatory chemokines
including PF4/CXCL4.31 P-selectin interacts with its receptor
P-selectin glycoprotein ligand-1 present on leukocytes and
endothelial cells, and mediates leukocyte recruitment to sites
of inflammation. In turn, leukocytes become activated and can
release other factors that stimulate platelets to secrete more
inflammatory mediators.31 Dysfunctional endothelium can
also express P-selectin, which is preformed and stored in the
Weibel-Palade bodies of endothelial cells.31 An increase in the
expression of P-selectin and platelet activation inpatientswith
DVT in the acute phase has been reported previously.32 The
present study thus indicates that residual platelet activation
persists in patients with previous DVT.
Fractalkine/CX3CL1 is a proinflammatory chemokine
expressed in several cell types including immune and
endothelial cells, and both experimental models and human
studies suggest that it may contribute to atherogenesis by
affecting leukocyte adhesion and migration. Proteolytic clea-
vage of the CX3CL1 mucin stalk close to the junction with the
transmembrane domain produces a soluble form of CX3CL1
that is a potent chemoattractant formonocytes and T cells, but
not for neutrophils,33 and which can interact with leukocytes
expressing its receptor CX3CR1. The ability of fractalkine/
CX3CL1 to both attract and arrest blood monocytes and
lymphocytes, as well as its presence in vascular wall cells,
makes this chemokine an obvious candidate to play a
pivotal role in atherosclerotic lesion formation. Against this
background, some studies using CX3CR1/apoE/ or
CX3CR1/LDLr/ mice have associated the substantial
decrease in macrophage infiltration within the arterial wall
with the marked reduction in atherosclerosis development,
Fig. 4 CX3CL1 receptor expression (CX3CR1) in circulating lympho-
cytes from DVT patients and age-matched controls. Heparinized
whole blood was co-stained with specific markers for lymphocytes and
CX3CR1. Blood samples were incubated or not with EDTA. Results are
expressed as (A, C) mean fluorescence intensity (MFI) and (B, D)
percentage of positive cells (n ¼ 23 age-matched controls, n ¼ 22
DVT patients). p < 0.05 relative to values in the control group.
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suggesting a relevant role for the CX3CL1/CX3CR1 axis in this
process.34,35 Consequently, CX3CL1/CX3CR1 axis has emerged
as a potential CV biomarker and a target for therapeutic
intervention. In line with our findings, upregulation of
CX3CL1 and CX3CR1 has been associated with plaque rupture
inpatientswith unstable angina pectoris.36More recently, in a
large cohort of patients from the Chronic Renal Insufficiency
Cohort (CRIC) study, Shah et al15 have showed that circulating
CX3CL1 levels may contribute to both atherosclerosis and
diabetes.15 To our knowledge, our study is the first report
showing an association between circulating CX3CL1 levels in
idiopathic DVT in humans and its potential involvement in
subsequent CV events.
A clinically relevant finding of our study was that, under
dynamic flow conditions, platelet–leukocyte adhesion to
TNFα-stimulated HUAECwas significantly more pronounced
in the DVT group than in controls, whereas no differences
were observed between the two groups when HUVECs were
used as endothelium. Our findings also suggest that platelets
are critical for leukocyte adhesion to dysfunctional arterial
endothelium, because in their absence no significant adhe-
sion differenceswere found between theDVT and the control
groups. In this regard, platelets induce leukocyte recruitment
in multiple inflammatory disorders, a property somehow
dissociated from their role in haemostasis.37 Therefore, in
DVT patients, platelet–leukocyte aggregates are likely
responsible for the arterial interactions detected since
TNFα-induced increased adhesiveness is partly dependent
on endothelial CX3CL1.38 Although monocytes and lympho-
cytes express CX3CR1,39 in the absence of platelets, CX3CL1/
CX3CR1 interaction had no functional role. Indeed, previous
studies performed by Schäfer et al demonstrated for the first
time the expression of CX3CR1 on platelets and provided
experimental evidence for a functional role of the chemokine
CX3CL1 in platelet activation and adhesion.40 Subsequently,
Schulz and colleagues showed that CX3CL1 expressed on
inflamed endothelial cells triggers the adhesion of leuko-
cytes under arterial shear conditions both in vitro and in
Fig. 5 TNFα induces CX3CL1 expression in human umbilical arterial endothelial cell (HUAEC) and human umbilical vein endothelial cell (HUVEC).
(A, B) Protein expression was determined by flow cytometry. HUAEC and HUVEC were stimulated with TNFα (20 ng/mL) for 24 hours. Results
(mean  SEM of n ¼ 4 independent experiments) are expressed as mean fluorescence intensity (MFI). p < 0.05 relative to values in the vehicle-
treated group. (C) CX3CL1 expression was visualized in HUAEC and HUVEC by immunofluorescence. Nuclei were counterstained with DAPI.
Results are representative of three independent experiments.
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atherosclerotic murine arteries in vivo.41 In agreement with
these observations, it seems that CX3CR1 expressing plate-
lets were strictly required for CX3CL1-induced leukocyte
adhesion in our experimental setting. It is also likely that
endothelial CX3CL1 may be involved in the activation of
surface-adherent platelets, the subsequent platelet degra-
nulation and P-selectin surface expression.
TNFα has several actions linking thrombosis to inflamma-
tion, includingdownregulationof thrombomodulin and stimu-
lation of tissue factor expression.42,43 Experimental studies
have demonstrated that combined neutralization of TNFα
and P-selectin reduces inflammation associated with venous
thrombosis.44Additionally, TNFα is one of themain inducers of
CX3CL1 expression.12 In agreement with these earlier observa-
tions, we found an increase in CX3CL1 protein expression in
primary arterial and venous endothelial cells stimulated with
TNFα. Moreover, CX3CL1 neutralization reduced the adhesion
of CX3CR1þ platelet–leukocyte aggregates to the arterial
endothelium, and this effect was more marked inwhole blood
from DVT patients. Two explanations may be offered for the
potential clinical impact of these results. First, an identified
mutant form of the CX3CL1 receptor, termed CX3CR1-M280, is
defective in mediating adhesive and chemotactic activity,45,46
and is linked to a lower risk of atherosclerosis, acute coronary
events and coronary artery endothelial cell dysfunction.45,46
Second, CX3CR1 upregulation has been detected in circulating
monocytes of patients with coronary artery disease.39 Given
these data, it is feasible that increased CX3CR1 expression/
function in circulating mononuclear cells attached to platelets
may establish a direct link between DVT and the development
of subsequent CV disorders.
In conclusion, young patients with a previous history of
idiopathic DVT have increased platelet activation and circu-
lating numbers of CX3CR1þ platelets, monocytes and lym-
phocyte bound to platelets, a mechanism that can contribute
to thehigher risk to develop atherosclerosis reported in some
studies. Blockade of CX3CR1/CX3CL1 axis in blood from DVT
patients reduced both platelet and leukocyte attachment to
dysfunctional arterial endothelium. Accordingly, the
CX3CL1/CX3CR1 axis may become a powerful tool in the
control of the arterial infiltration of mononuclear cells that
occur in thrombosis disorders.
What is known about this topic?
• Inflammatory mechanisms are involved in the acute
stage of DVT; however, considerably less is known
about the inflammatory status in the chronic phase
of the condition after the primary event in younger
patients.
• The role of CX3CL1/CX3CR1 axis in DVT has not been
previously investigated.
What does this paper add?
• CX3CL1 levels and CX3CR1 expression on platelets and
mononuclear cells is increased in younger patients
with a previous history of idiopathic DVT.
• Platelet–leukocyte and leukocyte adhesion to dysfunc-
tional endothelium depends on endothelial CX3CL1
upregulation.
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Fig. 6 A neutralizing antibody against CX3CL1 function inhibits the
recruitment of leukocytes to TNFα-stimulated human umbilical
arterial endothelial cell (HUAEC) but not human umbilical vein
endothelial cell (HUVEC). Leukocyte recruitment by TNFα-stimulated
HUAEC and HUVEC. HUAEC and HUVEC were stimulated with TNFα (20
ng/mL) for 24 hours. Some cells were incubated with a neutralizing
antibody against CX3CL1 function (5 μg/mL) or with the same con-
centration of an irrelevant isotype-matched monoclonal antibody
(MOPC21). Subsequently, whole blood from patients with DVT and
healthy age-matched controls incubated (A, B) without, or (C, D) with
EDTA, was perfused over endothelial monolayers for 5 minutes at 0.5
dyn/cm and leukocyte adhesion quantified (n ¼ 23 age-matched
controls, n ¼ 22 DVT patients). Values are expressed as the mean 
SEM. p < 0.05 or p < 0.01 relative to values in the vehicle-treated
cells; þp < 0.05 TNFα-stimulated cells in DVT group; p < 0.05 relative
to values of TNFα-stimulated cells in age-matched control group.
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